Extensive use of pharmaceutical contract manufacturing organizations (CMO) began in the 1990s, when European drug companies faced increased costs resulting from the expiration of many older drug patents, competition from the generic drug industry, and stricter government oversight of new drug development. Drug companies decided to reduce costs by outsourcing many processes previously done in-house, ranging from initial drug research studies to the entire manufacturing process. High costs for drug companies caused by patent expiration, generic drug competition and closer government supervision continue to fuel growth in pharmaceutical CMO.
The complaints about rising costs and quality issues connected with Indian and Chinese pharmaceutical CMOs have caused some pharmaceutical companies to stop working with them and instead sign contracts with CMOs operating in Europe. The pharmaceutical CMO marketplace remains highly competitive. Even if some contract manufacturing business is moved back to Europe from India and China, smaller European CMOs competing with Indian and Chinese CMOs may ultimately have to merge with each other, abandon particular specialties within pharmaceutical manufacturing, or quit the business completely in order to survive.
The Europe Pharmaceutical Contract Manufacturing market is poised to grow at a CAGR of 9.15% during the period 2015 to 2020. Active Pharmaceutical Ingredient (API) holds the highest market share while final dosage form is estimated to be the top growing segment during the forecasted period. The companies in the upstream industry are undergoing restructuring so as to focus more on R&D and added to this; stringent regulations on the Pharmaceutical industry are compelling the companies to outsource the manufacturing of the drugs. Pharmaceutical companies are going for less number of vendors to take volume advantage and at the same time reduce logistics costs.
The Europe Pharmaceutical Contract Manufacturing Market has been segmented on the basis of Dose Formulation Type (Solid Dose Formulation, Liquid Dose Formulation, and Injectable Dose Formulation), and Region (U.K., Germany, France, Italy, and Others). This report describes a detailed study of the Porter’s five forces analysis of the market. All the five major factors have been quantified using the internal key parameters governing each of them. It also covers the market landscape of these players which includes the key growth strategies, geographical footprint, and competition analysis.
The report also considers key trends that will impact the industry and profiles of leading suppliers of Pharmaceutical Contract Manufacturing Market. Some of the top companies mentioned in the report are Famar, Recipharm, Jubilant, Vetter, Pfizer CentreSource, Aenova, Catalent, Haupt Pharma, Baxter Bio Pharma Solutions, and among others.
Specialities Of This Report
1) The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.
2) The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.
3) The report contains wide range of information about the leading market players and the major strategies adopted by them.
Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received.
2. Executive Summary
3. MARKET OVERVIEW
3.2 Industry Value Chain Analysis
3.3 Industry Attractiveness - Porter's 5 Force Analysis
3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Consumers
3.3.3 Threat from new entrants
3.3.4 Threat from subsititute products
3.3.5 Competitive rivalry within the industry
3.4 Industry Policies
4. MARKET DYNAMICS
4.2.1 Growing Innovative drugs
4.3.1 In-house manufacturing
4.4.1 Final dosage form manufacturing
5. Pharmaceutical Contract Manufacturing Market Segmentation, Forecasts and Trends - by Revenue
5.1 By Dose Formulation Type
5.1.1 Solid Dose Formulation
5.1.2 Liquid Dose Formulation
5.1.3 Injectable Dose Formulation
5.2 By Region
22.214.171.124 United Kingdom
6. Europe Vendor Market Share Analysis
7. Competitive Intelligence - Company Profiles
7.5 Pfizer CentreSource
7.8 Haupt Pharma
7.9 Baxter Bio Pharma Solutions
8. Investment Analysis
8.1 Recent Mergers and Acquisitions
8.2 Investment Scenario and Opportunities
9. Future of Pharmaceutical Contract Manufacturing Market
LIST OF TABLES
1: Europe Pharmaceutical Contract Manufacturing market Revenue, 2014-2020 ($Billion)
2: Pharmaceutical Contract Manufacturing market Revenue, by Dose Formulation Type, Solid Dose Formulation, 2014-2020 ($Billion)
3: Pharmaceutical Contract Manufacturing market Revenue, by Dose Formulation Type, Liquid Dose Formulation, 2014-2020 ($Billion)
4: Pharmaceutical Contract Manufacturing market Revenue, by Dose Formulation Type, Injectable Dose Formulation, 2014-2020 ($Billion)
5: Pharmaceutical Contract Manufacturing market Revenue, by Country, United Kingdom, 2014-2020 ($Million)
6: Pharmaceutical Contract Manufacturing market Revenue, by Country, Germany, 2014-2020 ($Million)
7: Pharmaceutical Contract Manufacturing market Revenue, by Country, France, 2014-2020 ($Million)
8: Pharmaceutical Contract Manufacturing market Revenue, by Country, Italy, 2014-2020 ($Million)
9: Pharmaceutical Contract Manufacturing market Revenue, by Country, Others, 2014-2020 ($Million)